茶碱是COPD患者临床常用的平喘药物，其治疗窗很窄、个体差异很大。产生这种个体差异的原因却不是很清楚。CYP1A2酶是茶碱在体内的主要代谢酶,其基因存在遗传多态性。目前发现的CYP1A2功能性基因位点有四个，这些功能性位点与COPD患者茶碱的体内代谢是否相关，目前国际上的研究尚不多。因此本课题拟通过提取COPD患者外周血DNA,基因测序分析CYP1A2基因多态性，并通过临床试验获得COPD患者茶碱的药代动力学与临床疗效，探讨COPD患者CYP1A2不同基因型与茶碱体内代谢、临床疗效的差异。试图从药物遗传学的角度分析茶碱出现很大个体差异的原因，为茶碱的个体化用药提供理论依据。

As a conventional anti-bronchospasm drug for COPD patients，theophylline has a narrow therapy range and huge individual variation,but the reason is still unknown.Theophylline is primarily metabolized by CYP1A2 in vivo, There are polymorphisms in CYP1A2 gene.Four polymorphisms have been reported to be functional, however the investigations of whether there is relevance between the polymorphisms and the variation of theophylline in COPD patients are few. This study will extract the peripheral blood of COPD patients and analyze the gene polymorphisms of CYP1A2 through gene sequencing,and will get the pharmacokinetics parameters and clinical efficacy of theophylline through clinical trial in order to investigate the differences of metabolism and clinical effciacy of theophylline in different CYP1A2 gene types. We try to find the causes of the huge individual variation of theophylline from pharmacogenetics factors and make theory support for individual therapy of theophylline.